CD Antigens

Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized, IgG1-based bispecific antibody that targets the near-membrane extracellular domain of FcRH5 on multiple myeloma (MM) cells and CD3 on T cells. Additionally, Cevostamab promotes effective synapse formation, enhancing T cell killing activity against MM tumor cells.

Foralumab (NI-0401) is an orally effective humanized monoclonal antibody that targets CD3. Foralumab can modulate the immune response of human cells reconstructed from hematopoietic stem cells in NSG mice.

Muromonab is a monoclonal antibody that targets the CD3 receptor. It can block all cytotoxic T cell functions. Muromonab is also used as an immunosuppressant to reduce acute solid organ transplant rejection reactions.

Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody that targets CD2. Siplizumab can deplete T cells, reduce T cell activation, inhibit T cell proliferation and enrich naïve and bona fide regulatory T cells.

Talquetamab (JNJ-64407564) is a humanized bispecific antibody that can bind to both GPRC5D (a member of the G protein-coupled receptor family C5) and CD3, inducing T cell-mediated killing of MM cells expressing GPRC5 through recruitment and activation of T cells. Talquetamab (JNJ-64407564) has anti-tumor activity.